



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/555,860
				Filing Date	November 1, 2005
				First Named Inventor	Christopher P. Holmes
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	04279/100M213-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	USPD1	US-6,858,630	02-22-2005	Luengo et al.	
	USPD2	US-6,784,154	08-31-2004	Westenfelder	
	USPD3	US-6,783,965	08-31-2004	Sherman et al.	
	USPD4	US-6,660,843	12-09-2003	Feige, et al.	
	USPD5	US-6,583,272	06-24-2003	Bailon	
	USPD6	US-6,576,235	06-10-2003	Williams et al.	
	USPD7	US-6,552,167	04-22-2003	Rose	
	USPD8	US-6,552,008	04-22-2003	Duffy et al.	
	USPD9	US-6,531,121	03-11-2003	Brines, et al.	
	USPD10	US-6,506,362	01-14-2003	Dower et al.	
	USPD11	US-6,498,155	12-24-2002	Luengo et al.	
	USPD12	US-6,489,293	12-03-2002	Sytkowski, et al.	
	USPD13	US-6,465,430	10-15-2002	Dower et al.	
	USPD14	US-6,340,742	01-22-2002	Burg, et al.	
	USPD15	US-6,333,031	12-25-2001	Olsson et al.	
	USPD16	US-6,251,864	06-26-2001	Dower et al.	
	USPD17	US-6,211,608	04-03-2001	Raina et al.	
	USPD18	US-6,153,407	11-28-2000	Sytkowski, et al.	
	USPD19	US-6,121,238	09-19-2000	Dower et al.	
	USPD20	US-6,107,272	08-22-2000	Sytkowski	
	USPD21	US-6,103,879	08-15-2000	Chaovapong, et al.	
	USPD22	US-6,083,913	07-04-2000	Dower et al.	
	USPD23	US-6,077,939	06-20-2000	Wei et al.	
	USPD24	US-6,048,971	04-11-2000	Sytkowski, et al.	
	USPD25	US-5,986,047	11-16-1999	Wrighton et al.	
	USPD26	US-5,955,422	09-21-1999	Lin	
	USPD27	US-5,932,546	08-03-1999	Barrett et al.	
	USPD28	US-5,919,758	07-06-1999	Sytkowski	
	USPD29	US-5,869,451	02-09-1999	Dower et al.	
	USPD30	US-5,830,851	11-03-1998	Wrighton et al.	
	USPD31	US-5,773,569	06-30-1998	Wrighton et al.	
	USPD32	US-5,767,078	06-16-1998	Johnson et al.	
	USPD33	US-5,756,349	05-26-1998	Lin	
	USPD34	US-5,747,446	05-05-1998	Sytkowski	
	USPD35	US-5,683,983	11-04-1997	Barrett et al.	
	USPD36	US-5,677,280	10-14-1997	Barrett et al.	
	USPD37	US-5,672,662	09-30-1997	Harris et al.	
	USPD38	US-5,668,110	09-16-1997	Barrett et al.	
	USPD39	US-5,654,276	08-05-1997	Barrett et al.	
	USPD40	US-5,621,080	04-15-1997	Lin	
	USPD41	US-5,618,698	04-08-1997	Lin	
	USPD42	US-5,614,184	03-25-1997	Sytkowski, et al.	
	USPD43	US-5,580,853	12-03-1996	Sytkowski	

Examiner Signature	Date Considered
--------------------	-----------------

{W:\04279\100m213us1\00663504.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/555,860
				Filing Date	November 1, 2005
				First Named Inventor	Christopher P. Holmes
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	04279/100M213-US1

	FPD9	WO 01/91780	12-06-2001	Ortho-McNeil Pharmaceutical, Inc.		
	FPD10	WO 03/002716	01-09-2003	Mountain View Pharmaceuticals, Inc.		
	FPD11	WO 04/030617	04-15-2004	Mountain View Pharmaceuticals, Inc.		
	FPD12	WO 04/060299	07-22-2004	Mountain View Pharmaceuticals, Inc.		
	FPD13	WO 04/060300	07-22-2004	Mountain View Pharmaceuticals, Inc.		
	FPD14	WO 04/100997	11-25-2004	Affymax, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	NPLD1	Abuchowski, A., et al., "Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase," J. Biol. Chem, Vol. 252, pp. 3582-6 (1977)		
	NPLD2	Beauchamp, C.O., et al., "A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin", Anal Biochem., Vol. 131, pp. 25-33 (1983)		
	NPLD3	Chen, R.H., et al., "Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)", Biochem. Biophys. Acta., Vol. 660, pp. 293-8 (1981)		
	NPLD4	El-Sayed et al., "Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium", Pharm. Res., 2001, 18:23-28		
	NPLD5	Francis, G.E., et al., "PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques", Int. J. Hematol, Vol. 68, pp. 1-18 (1998)		
	NPLD6	Gestwicki et al., "Influencing receptor-ligand binding mechanisms with multivalent ligand architecture", J. Amer. Chem. Soc., 2002, 124:14922-14933		
	NPLD7	Johnson, D.L., et al., "Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity", Chem. Biol., Vol. 4, pp. 939-950 (1997)		
	NPLD8	Johnson et al., "Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1", Biochemistry 37: 3699-3710 (1998)		
	NPLD9	Kita, Y., et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma", Dr. Des. Deliv. Vol. 6, pp. 157-67 (1990)		
	NPLD10	Klajnert et al., "Dendrimers: properties and applications", Acta Biochimica Polonica, 2001, 48:199-208		

Examiner Signature	Date Considered	
-----------------------	--------------------	--

W:\04279\100m213us1\00663504.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/555,860
				Filing Date	November 1, 2005
				First Named Inventor	Christopher P. Holmes
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	04279/100M213-US1

	NPLD11	Knauf, M.J., et al., "Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers", J. Biol. Chem., Vol. 263, pp. 15064-70 (1988)	
	NPLD12	Lee, J.W., et al., "Reduction of azides to primary amines in substrates bearing labile ester functionality. Synthesis of a PEG-solubilized, "Y"-shaped iminodiacetic acid reagent for preparation of folate-tethered drugs", Org. Lett., Vol. 1, pp. 179-181 (1999)	
	NPLD13	Ramakrishnan et al., "Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers", J. Clin. Pharmacol., 2004, 44:991-992	
	NPLD14	Saifer, M.G., et al., "Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol", Adv. Exp. Med. Biol. Vol. 366, pp. 377-87 (1994)	
	NPLD15	Sasaki, et al., "Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA", Journal of Biological Chemistry 262:12059-12076 (1987)	
	NPLD16	Somack, R., et al., "Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41,000-72,000 daltons)", Free. Radic. Res. Commun. Vols. 12-13, pp. 553-62 (1991)	
	NPLD17	Tsutsumi, Y. et al., "Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity", J. Controlled Release, Vol. 33, pp. 447 (1995)	
	NPLD18	Veronese, F. M., "Peptide and protein PEGylation: a review of problems and solutions", Biomaterials 22:405-417 (2001)	
	NPLD19	Woller, N.C. et al., "The lectin-binding properties of six generations of mannose-functionalized dendrimers", Organic Letters 4:7-10 (2002)	
	NPLD20	Wrighton et al., "Small peptides as potent mimetics of the protein hormone erythropoietin", Science 273:458-463 (1996)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Andrew D. Kosar/	Date Considered	10/23/2009
-----------------------	-------------------	--------------------	------------

{W:\04279\100m213us1\00663504.DOC {XXXXXXXXXXXXXXXXXXXXXXXXXXXX}}

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/